CHE
CHEMED CORP
NYSE · Healthcare · Medical - Care Facilities · US
$547.45
+2.59%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.7B | 2.5B | 2.4B | 2.3B | 2.1B |
| Cost of Revenue | 1.8B | 1.8B | 1.6B | 1.5B | 1.4B |
| Gross Profit | 842.3M | 758.3M | 854.3M | 798.8M | 765.1M |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 446.5M | 417.2M | 424.4M | 395.1M | 358.7M |
| General & Admin Expense | 111.5M | — | 424.4M | 395.1M | 358.7M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 25.1M | — | 63.5M | 63.1M | 62.9M |
| Total Operating Expenses | 471.6M | 417.2M | 487.9M | 458.2M | 421.6M |
| Cost and Expenses | 2.3B | 2.2B | 2.1B | 1.9B | 1.8B |
| Operating Income (EBIT) | 370.9M | 338.2M | 366.5M | 340.6M | 343.5M |
| Non-Operating | |||||
| Interest Income | 3.0M | 8.7M | 14.6M | 6.3M | 355.0K |
| Interest Expense | 4.9M | 1.8M | 1.8M | 3.1M | 4.6M |
| Net Interest Income | (2.0M) | 7.0M | 12.8M | 3.2M | (4.2M) |
| Other Non-Op Income/Expense | 11.5M | 17.5M | 33.0M | 9.8M | (13.8M) |
| Non-Operating Income (excl Interest) | (7.7M) | (19.3M) | (34.8M) | (12.9M) | 9.2M |
| EBT (Pre-Tax Income) | 382.3M | 355.8M | 399.5M | 350.4M | 329.7M |
| Income Tax Expense | 99.9M | 90.5M | 97.5M | 77.9M | 80.1M |
| Bottom Line | |||||
| Net Income | 282.4M | 265.2M | 302.0M | 272.5M | 249.6M |
| Earnings from Cont. Ops | 282.4M | 265.2M | 302.0M | 272.5M | 249.6M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 282.4M | 265.2M | 302.0M | 272.5M | 249.6M |
| Per Share | |||||
| Basic EPS | $20.95 | $18.42 | $20.10 | $18.11 | $16.72 |
| Diluted EPS | $20.91 | $18.42 | $19.89 | $17.93 | $16.53 |
| Revenue Per Share | $203.79 | $175.72 | $161.83 | $150.46 | $143.01 |
| Shares | |||||
| Basic Shares Outstanding | 13.1M | 14.4M | 15.0M | 15.1M | 14.9M |
| Diluted Shares Outstanding | 13.1M | 14.4M | 15.2M | 15.2M | 15.1M |
| Profitability Metrics | |||||
| EBITDA | 446.1M | 422.4M | 464.3M | 414.3M | 393.4M |
| D&A | 67.6M | 64.8M | 63.0M | 60.9M | 59.2M |
| EBIT | 378.6M | 357.5M | 401.2M | 353.5M | 334.3M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026